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Abstract
Background: The DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders, 4
th edition Textrevision)
highlights the especially poor outcomes of early-onset conduct disorder (CD). The strong link between the
patient’s age at treatment and its efficacy points the importance of early intervention. Risperidone is one of the
most commonly studied medications used to treat CD in children and adolescents. The aim of this study is to
obtain preliminary data about the efficacy and tolerability of risperidone treatment in otherwise typically
developing preschool children with conduct disorder and severe behavioral problems.
Method: We recruited 12 otherwise normally developing preschoolers (ten boys and two girls) with CD for this
study. We could not follow up with 4 children at control visits properly; thus, 8 children (six girls, two boys; mean
age: 42.4 months) completed the study. We treated the patients with risperidone in an open-label fashion for 8
weeks, starting with a daily dosage of 0.125 mg/day or 0.25 mg/day depending on the patient’s weight (<20 kg
children: 0.125 mg/day; >20 kg children: 0.25 mg/day). Dosage titration and increments were performed at 2-week
interval clinical assessments. The Turgay DSM-IV Based Disruptive Behavior Disorders Child and Adolescent Rating &
Screening Scale (T-DSM-IV-S) as well as the Clinical Global Impression Scale (CGI) assessed treatment efficacy; the
Extrapyramidal Symptom Rating Scale (ESRS) and laboratory evaluations assessed treatment safety.
Results: The mean daily dosage of risperidone at the end of 8 weeks was 0.78 mg/day (SD: 0.39) with a maximum
dosage of 1.50 mg/day. Based on the CGI global improvement item, we classified all patients as “responders” (very
much or much improved). Risperidone was associated with a 78% reduction in the CGI Severity score. We also
detected significant improvements on all of the subscales of the T-DSM-IV-S. Tolerability was good, and serious
adverse effects were not observed. We detected statistically significant prolactin level increments (p < 0.05), but no
clinical symptoms associated with prolactinemia.
Conclusion: The results of this study suggest that risperidone may be an effective and well-tolerated atypical
antipsychotic for the treatment of CD in otherwise normally developing preschool children. The findings of the
study should be interpreted as preliminary data considering its small sample size and open-label methodology.
Background
Conduct disorder (CD); the most severe type of disrup-
tive behavior disorders (DBDs); is among the most com-
mon psychiatric disorders in childhood and adolescence.
CD accounts for 30% to 50% of child and adolescent
referrals in some clinics [1,2]. According to a recent sur-
vey using Diagnostic and Statistical Manual of Mental
Disorders, 4
th edition Textrevision (DSM-IV-TR) cri-
teria, the prevalence of CD combined with oppositional
defiant disorder (ODD) is approximately 5% [3]. The
DSM-IV-TR states that CD is characterized by a repeti-
tive pattern of behavior that violates the rights of others
or societal rules. The main four symptom categories of
the disorder are: physical aggression or threats of harm
to people or animals; destruction of property; acts of
deceitfulness or theft; and serious violations of age-
appropriate rules [4].
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with unfavorable outcomes. A 7-year longitudinal study
of children with conduct disorder showed that less than
15% of the sample recovered by mid-to-late adolescence
[5]. Other longitudinal studies have reported that 45%
to 90% still met diagnosis criteria 3 to 4 years later [6].
According to other research reports, 40% of patients
with CD are diagnosed with antisocial personality disor-
der as adults and may have a criminal record. Of those
who do not, most manifest significant functional impair-
ments in their relationships and at work [6]. These
patients are also at great risk for developing substance
use and mood, anxiety or somatoform disorders [7].
The DSM-IV divides CD into two categories accord-
ing to the age of onset: childhood- and adolescent-
onset. The DSM-IV-TR also highlights the poor
outcomes for children whose behavior problems begin
early in life. Youths with childhood-onset CD are more
likely to exhibit persistent antisocial behaviors and
higher rates of aggression. A prognosis of childhood-
onset CD may be related to the impairment of academic
and social performance during a period of mental and
behavioral maturation [8].
There is no longer doubt that disruptive behaviors
emerge in early childhood and exhibit moderate stability
[9]. The appropriateness of applying DSM-IV diagnostic
criteria for CD to preschool children, however, is an area
of controversy [10]. Noncompliance and aggression are
more common in early childhood compared to other
developmental periods; thus, some authors have argued
that atypical behaviors in preschool children may be tran-
sient developmental perturbations [11], whereas others
have suggested that these behaviors may be a disturbance
of the parent-child relationship [12]. Other concerns have
centered on whether young children are developmentally
capable of engaging in the behaviors that characterize the
disorder and whether a functional equivalents of these
behaviors exists across the time [10]. In their review of the
evidence for the construct validity of DSM-based ODD
and CD diagnoses, Keenan and Wakschlang (2002)
emphasized that the determination of abnormality rests on
establishing impairment in normal developmental func-
tioning. A behavior’s pervasiveness and intensity is critical
to this determination [10]. The essential features of CD
(i.e., violation of rules and the rights of others, aggressive-
ness and destructiveness) are applicable to preschool chil-
dren because they are able to understand the concept of
rules and can control their behavior accordingly [10,13].
To conclude, the authors stated that with some modifica-
tion based on the child’s developmental level, the DSM
framework is a valid method for identifying preschool chil-
dren with disruptive behaviors [10].
Kim-Cohen et al. labeled patients who met five or
more CD criteria as having “moderate to severe” CD in
their study for the validation of CD in 4.5-5 year-old
children [14]. They found prevalence of the normal
range of CD and “moderate to severe” CD among 4.5-5
year-old preschoolers as 6.6% and 2.5% respectively. In
another study that compared referred and non-referred
2.5- to 5.5-year-olds, the prevalence of CD was 2% in
the non-referred group and 41.8% in referred group. In
the same study, the prevalence rates for ODD were 2%
and 72.2% in the non-referred and referred group,
respectively. DSM-IV symptoms of ODD and CD may
distinguish referred from non-referred preschoolers in a
pattern similar to that in older children. This possibility
suggests that DSM-IV nosology is a valid diagnostic
system for discriminating between typical and atypical
disruptive behaviors in preschoolers [15].
T h ep r e d i c t i v ev a l i d i t yo fC Di np r e s c h o o l e r sh a sa l s o
been documented. Preschoolers diagnosed with CD con-
tinue to have behavioral and educational problems 2
[14] and 5 years later [16] regardless of whether they
have CD symptoms at follow up. In addition, the effect
sizes between CD and its risk factors are comparable to
those reported in older children [14,17]. Interventions to
prevent chronic CD can be effective if applied early in
life [18]. Kim, Cohen et al. (2005) showed that a mini-
mum of DSM-IV-TR CD criteria were sensitive enough
to identify preschoolers who might benefit from inter-
vention [14].
Treating CD is important for several reasons. First of
all, its symptoms may lead to severe difficulties in school
life, social development and adult health, as mentioned
above [19,20]; Second, the increased risk of physical
injuries may be life-threatening for the patient and their
victims. The large prevalence of CD and its adverse out-
comes, the considerable stability continuity of diagnosis
over time [1] and the risk of escalating aggressive and
antisocial behavior in untreated patients [20] have direc-
ted many researchers to this topic in recent years.
Treating CD should begin when the patient is diagnosed
with CD because appropriate early interventions affect
the disease’s prognosis [18]. A review of multimodal
treatment approaches for CD showed a strong link
between the efficacy of treatment and the age of
the patient at intervention, which demonstrates the
value of early treatment [21]. Treatments should include
multidisciplinary interventions due to the frequent co-
occurrence of a number of biological, functional and
psychosocial risk factors in the development of CD.
Psychosocial therapies like behavioral therapy, psy-
chotherapy and parental counseling and augmentation
with pharmacotherapy are the most commonly used
treatment modalities [22]. The presence of aggressive
behavior in youths with a primary diagnosis of CD
demonstrates the need for augmentation psychosocial
therapy with pharmacotherapy [23].
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mood stabilizers are the medical agents used to treat
CD and aggression. Most of these treatments have been
shown to have some efficacy, although the expected side
effect profile and decrease in symptom severity asso-
ciated with each agent determines their differences.
Among these, both typical and atypical antipsychotics
can control the aggression and explosiveness of CD, but
only typical antipsychotics are associated with the risk
of extrapyramidal symptoms and tardive dyskinesia [24].
Mood stabilizers including lithium, carbamazapine and
valproic acid have a variety of effectiveness in trials ran-
ging from significant to minor decreases in symptom
severity [8,25]. The need to closely monitor patients’
blood drug level-especially in the case of lithium-has
deterred its use in pediatric patients with CD. Stimu-
lants (mostly methylphenidate) are also effective for
controlling aggression, but these drugs are usually pre-
ferred in cases of CD comorbid with ADHD [26,27].
Two recently conducted reviews condensed the pharma-
cotherapy of CD and aggression [25,28]. In the first
meta-analysis conducted by Ipser and Stein, lithium and
the atypical antipsychotic risperidone were found to be
effective in treating CD on both global measures and
symptom severity. Risperidone was effective and demon-
strated a safe side-effect profile. In the second review,
Pappadopulos et al. reviewed all randomized controlled
trials that were conducted with aggressive youths (i.e.,
age < 19). The diagnoses of the patients included mostly
DBD, CD and ADHD, but other disorders with aggres-
sion as a core symptom were also included in this study.
The atypical antipsychotic group, all of whom were pre-
scribed with risperidone (nine trials), exerted a notably
large overall Cohen’s d effect size (mean ES = 0.9). Typi-
cal antipsychotics (two trials with haloperidole and one
trial with thioridazine) exerted a medium ES (mean ES
= 0.7). The ES for mood stabilizers (five trials with
lithium and one trial with carbamazepine) was moderate
(ES = 0.4); the variability in the efficacy of lithium was
notable (ESs ranged between 0.0 and 0.9). Trials with
stimulants (mostly methylphenidate over 20 trials) were
conducted mostly with patients with a primary diagnosis
of ADHD with comorbid DBD. Stimulants exerted a
medium to large effect on pediatric aggression (mean ES
= 0.78). Lastly, we reviewed four randomized controlled
trials with atomoxetine and found the ESs to be small
(mean ES = 0.18), implying that atomoxetine does not
effectively control aggression.
Risperidone, which is an atypical antipsychotic with
the potent properties of 5-HT2 and D2 receptor antago-
nists, is the most commonly studied agent in studies
using the following designs: short-term double-blind,
randomized and controlled in children and adolescents
[7,19,24]; long-term and open-label [29-31]; and long-
term, randomized, double-blind and placebo-controlled
[32]. The results of these studies suggest that risperi-
done is an effective treatment of behavioral disturbances
in children and adolescents with CD and that the bene-
fits of this agent endure during maintenance treatments.
Note that most of these studies were conducted using
children with below average IQs.
A pooled analysis of the data obtained from two stu-
dies [7,19] on the effects of risperidone in children with
below average IQs and DBD diagnoses showed that ris-
peridone produced improvement in both social compe-
tence and problematic behavior (e.g., insecure/anxious
and conduct problems), whereas affective insecurities
(e.g., shy, timid, clings to adults, crying or tearful epi-
sodes) failed to improve [33].
Risperidone was also studied for its control of aggres-
sion in children and adolescents with bipolar disorder
[34,35] and pervasive developmental disorder [36-39].
Again, risperidone was effective and safe in these trials
and demonstrated a good side-effect profile, especially
in low doses.
The treatment of CD in preschoolers lacks sufficient
data and needs more care starting with diagnostic
assessments. Proper developmental and functional
assessment is crucial. Due to the lack of controlled trials
and complete medication use evidence, psychotherapeu-
tic interventions with the aim of increasing parenting
skills or other therapy modalities such as behavioral
therapy with parental involvement are recommended as
first-line interventions in typically developing children.
Carefully monitored medication is a second-step treat-
ment for children with moderate to severe symptoms
and functional impairments that persist after appropriate
psychotherapeutic interventions [40]. Risperidone is
recommended as the first medication choice for treating
children with DBD with severe aggression without co-
occurring ADHD [19,32,40,41].
In the few studies that have conducted risperidone trials
in preschoolers, it was shown to be an effective and well-
tolerated treatment. Furthermore, in an open-label 8-week
trial using patients with bipolar disorder [42], an open-
label 16-week trial using patients with pervasive develop-
mental disorder [43], and a 6-month randomized placebo-
controlled trial using patients with pervasive developmen-
tal disorder [39], risperidone was found to be beneficial
and safe in low doses with no serious side effects in pre-
schoolers; however, these trials reported significant gains
in weight and prolactin levels. A 3-year follow-up study
conducted in 53 preschoolers with pervasive developmen-
tal disorders revealed that risperidone effectively controls
behavioral disorders and affect dysregulation in the long
term [44]. Increased prolactin levels without clinical signs
and an increased appetite were the most frequent side
effects. One retrospective study of children with aggression
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decrease of 36% in the severity of symptoms after using
risperidone [45].
Developmentally inappropriate and severe behavioral
disturbances are present in preschoolers [9]. These dis-
turbances may severely interfere with relationships,
social functioning and the development of the child.
The DSM-IV criteria for conduct disorder are valid for
this age group. Treating these children is crucial consid-
ering the remarkable stability of their symptoms, the
risk for a future comorbid diagnosis and the efficacy of
early interventions. Pharmacotherapy is needed when
psychotherapic interventions are not successful. Some of
our data suggest that risperidone treatments control
aggression in this age group, but more evidence of this
treatment’s efficacy and tolerability in typically develop-
ing children with conduct disorder is needed.
In this open-label trial, we aimed to obtain prelimin-
ary data about the tolerability and efficacy of risperidone
monotherapy in otherwise normally developing pre-
schoolers with CD and severe behavioral problems.
Furthermore, we sought to construct the baseline data
for an extension study. To our knowledge, this study is
the first to evaluate risperidone monotherapy in the
treatment of preschoolers with both CD and normal
intelligences.
Method
We designed this study as an 8-week, open-label, single
center trial. The Ethics Committee of the University
approved the study procedure, and the study was con-
ducted in accordance with the principles of the Declara-
tion of Helsinki. All participants’ parents gave written
informed consent prior to the treatment.
All of the study procedures were completed at the Ege
University School of Medicine Department of Child and
Adolescent Psychiatry. This study center is a central
medical school and tertiary referral hospital located in
Izmir (population approximately 3 million), in Turkey.
We determined participants from the patients referred
to the study center from the two main state hospitals of
Izmir as “treatment resistant and severely disturbed”.
These state hospitals have a low socioeconomic catch-
ment area. Two child and adolescent psychiatry specia-
lists evaluated and treated the patients at these
hospitals’ outpatient clinics. Patients who were diag-
nosed with conduct disorder and ADHD during their
outpatient policlinic visits were recruited for the present
study. Prior to referral, all patients had psychotherapeu-
tic interventions to some extent, including parent train-
ing. Moreover, they were treated with a psychostimulant
medication (i.e., short-acting methylphenidate). All par-
ticipants were defined as “treatment resistant,” having
received minimal or no benefit at all from the previous
treatment. No participants were on medication at the
time of referral to our study center.
The senior author, an experienced child and adoles-
cent psychiatry specialist, first assessed all children in
the outpatient clinic of the university at recruitment, fol-
lowed by two child and adolescent psychiatry residents.
The senior author first interviewed children and then
applied the Turkish version of the Kiddie-SADS Lifetime
Version (K-SADS-PL) [46,47]. Although the K-SADS-PL
is a semi-structured interview for use with school-age
children, the K-SADS-E (Epidemiologic version) has
previously been used to ascertain specific diagnoses,
including ODD and CD in preschoolers [15]. In this
study conducted by Keenan and Wakschlag some modi-
fications to the K-SADS-E were made for the purpose of
providing developmentally appropriate operational defi-
nitions. For example, to qualify as having stolen some-
thing, they did not require the item to be of non-trivial
value as stated in DSM-IV because preschoolers do not
usually attempt to take expensive items. Weapon use
included sticks, rocks or bats. The participant age group
in this study was very similar to our study group (mean
age: 48 months versus 42 months, respectively) [15].
Another study applied the DSM-IV symptoms of CD to
preschoolers; these symptoms included fighting, bully-
ing, lying, stealing, behaving cruelly toward people or
animals, vandalizing and violating rules [14]. The
“forced sexual activity” item was excluded because it
was deemed inappropriate for this age group [14]. Bir-
maher et al. (2009) completed a psychometric study to
assess the reliability of the K-SADS-PL in preschoolers
and suggested that the K-SADS-PL is a reliable tool to
evaluate DSM-IV psychiatric disorders in preschoolers
[48]. The use of the K-SADS in preschool may reduce
method variance when trying to establish continuity and
discontinuity between conditions in preschool and later
in childhood [49].
In our study, we also modified “weapon use” (i.e.,
stone, stick, bat) and “stealing” (including trivial belong-
ings) in line with Keenan and Wakschlag (2004) [15]. In
actuality, most of the weapon-brandishing children used
knifes with the intention of threatening others. Fighting,
bullying, lying, behaving cruelly toward people or ani-
mals, destroying property and violating rules were beha-
viors present in most of the participants. (The rule
violation criterion is considered to be present if the
child knowingly breaks the rules at home or elsewhere.
Most of the children’s parents stated that they did not
accept guests to their homes or felt unable to shop at
markets with their children because they do not behave
in age-appropriate ways.) Stealing (without confronta-
tion) and fire setting were present in three children.
Two children were reported to have run away from
home many times during the day despite their parents’
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stealing with confrontation, were not present in any of
the children. (Note that preschool education is not obli-
gatory in Turkey, and none of the children attended
school. All of the parents reported that they could not
send their children to school because of the behavioral
problems; thus, truancy could not be evaluated.)
We diagnosed 16 children (13 boys 3 girls) with CD.
All children had a comorbid ADHD diagnosis. Other
psychiatric disorders that might have been present with
temper tantrums or aggression (e.g., affective disorders)
were ruled out following the K-SADS-PL. That same
day, a comprehensive interview was performed with the
parents. Furthermore, we took a complete medical,
developmental and psychiatric history from the children.
All of the children were from middle or low socioeco-
nomic class families. Poor parenting, abuse, and negative
family experiences contribute to the development of CD
[50]; however, other than a low socioeconomic level, we
did not detect any additional risk factors (e.g., abuse,
neglect, physical violence, or parent rejection). Two
mothers were taking antidepressants. Observations of
the children in both a playroom and during the psychia-
tric assessment supported the psychiatric history in
terms of aggressive behaviors and developmental charac-
teristics. The children’s medical history revealed that all
of the children were severely aggressive toward their
parents and other children. They bit, beat, kicked,
scratched, threatened, swore at people, threw objects or
stones at them, and frequently initiated fights, and some
were violent toward animals. They lied, played with
matches, used knifes, and broke and harmed furniture
and belongings. Table 1 shows some of the children’s
demonstrative behavioral problems.
Parents of participants were offered a chance to take
part in a parent-training program developed by Ercan
and Aydın (1999) [51]. This program was based on Bark-
ley’s (1997) work and attempted to educate parents and
other members of the family about disruptive behavior
disorders and provide them with effective behavior-man-
agement techniques [52]. The program consisted of eight
meetings (four consecutive weekly meetings, followed by
four monthly meetings). Parents of four children stated
that they would not be able to attend the meetings due to
financial problems; thus, we excluded these children from
the study. Parents of remaining 12 children attended the
meetings. Eight parents attended more than 75% of the
program; the other four attended more than 50%. No
parents reported receiving a remarkable benefit at the
end of the program. Socioeconomical problems might
have contributed to the insufficient attendance. Further-
more, disadvantaged sociocultural characteristics might
have prevented the parents from gaining the expected
benefits of the program. At this point in the study, medi-
cations were offered to the parents for their children. We
informed parents about the study; subsequently, they
agreed to participate. The study began after the parents
signed a written informed consent. All of the children
were outpatients, and none were using medication at the
beginning of the study.
The study began with 12 children (ten boys, two girls).
At the first visit, a pediatrician neurology specialist per-
formed a complete physical and neurologic examination;
EEG and ECGs were taken, and blood biochemistry, a
complete blood count and prolactin levels were evalu-
ated to rule out any neurological and medical illnesses
that could create a medication contraindication. None
of the children demonstrated any laboratory assessment
Table 1 Patient sociodemographic characteristics and behavioral problems
No Age
(month)
Sex Socioeconomic
Status
Severe Behavioral Problems
1 30 F Low Has punched her eardrum with matchstick, has drunk chemical cleaning agent, bits and kicks her peers,
throws objects to people around.
2 44 F Middle Has started fire at home. Plays with knife, and is offensive. Her mother tells that she has been taking
depression treatment due to the stress she has been living with her girl.
3 51 M Middle Has jumped from the balcony being “Batman”. He usually lies, swears people and is very aggressive against
his peers.
4 72 M Low Has been plucking his brother’s hair, which has resulted in a localized alopecia. He kicks everybody at home.
The family cannot accept guests to home due to this boy’s offensive behaviors.
5 44 M Low Kicks his peers, plays with knife and runs after people with a knife in his hand, and tells that he’s going to
kill them.
6 38 M Low Climbs on to TV and jumps over, once almost fall under it. Throws objects to people, swears.
7 31 M Low Kicks and bites his parents at home, usually lies and is aggressive even against to older children. He is a
famous child around.
8 29 M Low Plays with knife and matches. Spites and bites peers. His mother told that last time he pick up a knife from
the kitchen and run after his grandfather shouting “I’ll kill you”!
F:Female, M:Male.
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examinations.
To identify a developmental delay, an experienced psy-
chologist administered the Ankara Developmental
Screening Inventory (ADSI) on all participants. The
ADSI consists of 154 items and measured the general
development of the child using the sum of its four sub-
scales: language/cognitive, fine motor, gross motor and
social capability/self-attention. The inventory is obtained
using the responses of the mother or the primary care-
giver of the child on each item. The ADSI was devel-
oped using items from similar inventories from other
countries, and its validity and reliability have been
demonstrated in Turkish children [53]. One of the sub-
scales assesses the child’s cognitive level and provides
data if there are any developmental delays in intellectual
ability. Children with normal IQs were defined as those
without developmental delays in general or normal cog-
nitive development levels at the end of the assessment.
None of the participants were diagnosed with a develop-
mental disability, but two children had a minimal speech
disability. Because other developmental properties were
normal for their age group, we did not exclude them
from the study.
We defined the inclusion criteria as follows.
1. Participants must be within the preschool age
range. (In Turkey, the preschool age group is defined
as 3-6 year-olds.)
2. Participants must be diagnosed with conduct dis-
order (comorbid ADHD diagnosis is allowed; other
psychiatric diagnosis are not allowed).
3. Participants must be severely ill (CGI Scale score
6 or higher).
4. Participants must fail to respond to the parent-
training program.
5. Participants must not be medicated at the time of
entry (although all children had recently used a
short-term short-acting methylphenidate).
6. Participants must be otherwise developmentally
normal.
7. Participants cannot have an abnormality on any
medical examination.
8. Parents must sign the written informed consent.
We treated all patients with risperidone starting with
a daily dose of either 0.125 mg/day or 0.25 mg/day,
depending on the weight of the child (<20 kg and
≥20 kg, respectively). The dosage amounts and medica-
tion schedule was based on Findling et al. (2000), who
used a double-blind method to treat children with CD
[24]. We made efficacy and side effect assessments in
the study center at 2-week intervals with the aim of
receiving more information and preventing unwanted
events. Parents were called for brief telephone inter-
views each week. Medications were regulated individu-
ally; twice a week, an incremental dosage titration was
made until we observed optimal therapeutic effects.
We planned not to exceed a maximum 2-mg/day
dosage. This maximum dosage was based on Bieder-
man et al. (2004), who conducted an open-label
8-week trial using preschoolers with bipolar disorder
[34]. We conducted final assessments at the end of
Week 8. Psychotropic drugs other than risperidone
were not allowed during the study.
Four children did not follow up the control visits
properly. Their parents were called and briefly inter-
viewed about the effects and side effects of the medica-
tion over the telephone. Parents did not report
insufficient responses or adverse events due to the medi-
cation; however, because safety and efficacy assessments
were not obtained regularly, we excluded these children
from the study. All other participants (six boys and two
girls) completed the study. Table 1 shows participant
sociodemographic characteristics.
Efficacy and Side Effect Assessments
1. Efficacy assessments
Two scales assessed disease severity and improvement.
1) The clinician completed both the Severity (CGI-S;
1 = not ill, 7 = severely ill) and Improvement subscales
(CGI-I; 1 = much improved, 7 = much worse) of the
Clinical Global Impression Scale [54]. Lower scores
reflect a reduced psychopathology and greater therapeu-
tic effectiveness. The CGI-S was filled out at the begin-
ning, during Week 4 and at the end (Week 8) of the
study. The CGI-I was filled out during Weeks 4 and 8.
2) The Turgay DSM-IV Based Child and Adolescent
Behavior Disorders Screening and Rating Scale, clinician
and parent forms (T-DSM-IV-S-C & T-DSM-IV-S-P)
assesses inattention (IA; nine items), hyperactivity-
impulsivity (HI; nine items), opposition-defiance (OD;
eight items) and conduct disorder (CD; 15 items) on a
4-point Likert-type scale (0 = not at all, 1 = just a little,
2 = quite a bit, and 3 = very much). Turgay et al. devel-
oped this scale, and Ercan et al. translated and adapted
it for Turkish [55,56]. The T-DSM-IV-S is based on the
DSM-IV diagnostic criteria. Greater scores reflect
increases in symptom severity. The clinician and parents
completed their respective forms of the scales at the
beginning of the study, during Week 4 and at the end of
the study.
The senior author, who also adapted and translated
the T-DSM-IV-S into Turkish, scored each efficacy
scale. “Response to medication” was defined as a 30%
reduction in symptoms according to the T-DSM-IV-S
or as having been judged as at least much improved on
the CGI-I (i.e., ≤2).
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1) Laboratory tests: Complete blood counts (CBC),
blood biochemistry (including liver and kidney function
tests, electrolytes and fasting glucose level), and prolac-
tin levels were measured at the beginning and end of
the study.
2) ECGs were recorded at the beginning and at the
end of the study.
3) Child body weight was measured to assess weight
change at the beginning of the study and at 2-week
intervals.
4) The Extrapyramidal Symptom Rating Scale [57]
assessed extrapyramidal adverse events. The clinician
completed this scale at 2-week intervals, beginning dur-
ing the second week of the study. In addition, a neurolo-
gic examination was performed at each visit to detect
whether extrapyramidal side effects were present.
5) For capturing adverse effects the authors developed
a checklist to evaluate probable adverse effects reported
in the previous literature. The last item asks for any
other side effect that is not present on the checklist.
Symptom severity is scored on 4-point Likert scale (0 =
not at all, 1 = mild, 2 = moderate, 3 = severe). The clin-
ician assessed the patient at each visit by asking the
items on the checklist one by one.
Analytical Procedures
Statistical analyses were conducted using SPSS 13.0. Sta-
tistical analyses comprised paired-sample t-tests and
one-way repeated-measures analysis of variance (ANO-
VAs). We adapted the LSD correction for pairwise com-
parisons. We considered P < 0.05 to be statistically
significant.
Results
The participant mean age was 42.4 (SD = 14.3) months.
Two children were female, and the others were male.
At the end of 8 weeks, the mean risperidone dose was
0.78 mg (SD = 0.39). The maximum dose was 1.50 mg/
day, which was achieved in only one child. Risperidone
doses used in this study were low; five children (62.5%)
received less than 1 mg/day, two children (25%) received 1
mg/day and one child (12.5%) received 1.5 mg/day.
Efficacy
After 8 weeks, we observed clinically significant
improvements in all patients. The mean CGI-S score
was 6.4 (SD = 0.5) at the beginning of the study (all par-
ticipants were severely ill, scoring 6 or 7 on the CGI-S).
At the end of the study, the mean CGI-S score was 1.4
(SD = 0.5). Risperidone was associated with a 78%
reduction in the CGI-S score (p < 0.001). All of the chil-
dren had greatly improved (CGI-I scores of 1 or 2).
According to the T-DSM-IV-S, there was a total score
reductions of 37.8 and 40.8 on the parental and clinical
forms, respectively (SD = 19.2, p = 0.001; SD = 15.3, p <
0.001). All of the patients were classified as “responders”
according to both the CGI and T-DSM-IV (parent and
clinician) scales. We found statistically significant
improvements on all subscales of the clinical and paren-
tal forms of the T-DSM-IV-S. Figures 1 and 2 as well as
Table 2 show the mean scores of these scales with their
comparisons at baseline as well as Weeks 4 and 8.
Tolerability
All of the children tolerated the medication well. Parents
of two children reported a mild to moderate sedation that
disappeared after two weeks. The sedation was not present
at the clinical visit, and neurologic examinations were nor-
mal. Sedation occurred after the first medication, and slee-
piness occurred during the daytime. Sedation symptoms
improved after 3 to 4 days and disappeared in a week.
Sedation was not observed in the other children.
We did not observe a significant or clinically relevant
weight gain in participants. Only one child gained 5.1%
of their weight; all of the others gained less than 5%. The
mean weight gain (±SD) from baseline was 0.3 ± 0.3 kg
(p = 0.061; mean weight at baseline was 16.0 ± 3.4 kg)
Liver and kidney function, fasting blood glucose levels,
blood electrolytes, complete blood count measurements
and ECG recordings did not change over the duration
of the study.
We detected a statistically significant, seven fold increase
in prolactin levels at the end of the study. The mean
change of prolactin was 33.9 ± 23.5 ng/ml (p < 0.05). The
baseline mean prolactin level was 5.3 ± 1.4 ng/ml, and at
Week 8, the mean prolactin level was 70.0 ± 21.9 ng/ml.
Six children (one girl, five boys) had prolactin levels above
0
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Figure 1 T-DSM-IV-Parent Mean Scores. IA: Inattention, H-I:
Hyperactivity-Impulsivity, OD: Opposition defiance, CD: Conduct
disorder
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Page 7 of 12the upper normal limit, but no participant showed clinical
signs of hyperprolactinemia.
Nausea, vomiting, sedation and acute dystonic reac-
tion developed in a patient who mistakenly received a
high dose of risperidone (the patient’sm o t h e rg a v eh i m
a dose of 2.5 mg, instead of 0.25 mg, 0.01 mg/kg). The
child’s mother explained that after her child received
the medication, the boy said he was feeling pain mostly
in his neck and that upper extremity movements were
difficult. The child and his mother were referred to the
nearest hospital, and an intramuscular medication
(biperidene) was given to the child. The pain, movement
difficulty and muscle hardness were resolved in half an
hour; however, the sedation and nausea lasted for nearly
one day. Vomiting also occurred on the same day. The
child visited our clinic the next day; his neurologic
examination was normal, and extrapyramidal symptoms
were absent. The patient was not started on oral biperi-
dene because there were no symptoms. The risperidone
treatment was stopped for a week, and the patient was
monitored closely. No symptoms reoccurred. Risperi-
done tolerance was good after restarting the treatment
one week later. None of the other children presented
neurological side effects or extrapyramidal symptoms.
Discussion
This study was a prospective open-label trial of risperi-
done to treat severe behavioral problems in preschoolers
with CD who were otherwise developmentally normal.
All 8 children (100%) were considered responders after
8 weeks of the trial.
We observed a gradual decline in scores on both the
parent (P) and clinician (C) scales on all four symptom
0
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8th week
Figure 2 T-DSM-IV-Clinician Mean Scores. IA: Inattention, H-I:
Hyperactivity-Impulsivity, OD: Opposition defiance, CD: Conduct
disorder
Table 2 Comparison of mean (SD) scores at baseline, Week 4 and Week 8
Scale Subscale Rater Baseline* Mean(SD) 4
thweek Mean(SD) 8
thweek Mean(SD) F Pairwise comparisons
T-DSM-IV-S IA P 16.1(6.3) 9.6(4.1) 8.5(3.6) 6.129 8
th < Baseline(p = 0.021)
C 18.9(5.1) 13.9(1.8) 10.1(2.1) 22.561 4
th < Baseline(p = 0.08)
8
th < Baseline(p = 0.01)
8
th <4
th(p = 0.01)
T-DSM-IV-S H-I P 22.6(4.5) 13.0(5.4) 11.0(3.3) 17.452 4
th < Baseline(p = 0.07)
8
th < Baseline(p < 0.001)
C 21.6(2.8) 12.8(4.2) 9.6(2.8) 23.098 4
th < Baseline(p = 0.004)
8
th < Baseline(p < 0.001)
T-DSM-IV-S OD P 16.9(5.4) 10.9(6.2) 8.3(2.9) 11.818 4
th < Baseline(p = 0.039)
8
th < Baseline(p < 0.001)
C 17.4(2.8) 11.4(2.8) 7.1(1.4) 33.126 4
th < Baseline(p = 0.001)
8
th < Baseline(p < 0.001)
8
th <4
th(p = 0.017)
T-DSM-IV-S CD P 14.0(8.6) 5.1(4.9) 4.0(2.1) 8.924 4
th < Baseline(p = 0.033)
8
th < Baseline(p = 0.007)
C 14.0(4.8) 7.4(2.9) 4.5(2.4) 16.119 4
th < Baseline(p = 0.012)
8
th < Baseline(p = 0.001)
T-DSM-IV-S Total P 69.5(19.1) 38.9(19.1) 31.8(8.8) 13.393 4
th < Baseline(p = 0.020)
8
th < Baseline(p = 0.001)
C 71.9(12.7) 46.9(11.1) 31.0(5.6) 30.410 4
th < Baseline(p = 0.003)
8
th < Baseline(p < 0.001)
8
th <4
th(p = 0.015)
CGI Severity C 6.4(0.5) 1.8(1.0) 1.4(0.5) 165.444 4
th &8
th < Baseline (p < 0.001)
CGI Improvement C 2.5(0.5) 1.8(0.7) 1.4(0.5) 6.785 4
th > Baseline(p = 0.048)
8
th > Baseline(p = 0.002)
T-DSM-IV-S: Turgay DSM-IV Based Child and Adolescent Behavior Disorders Screening and Rating Scale; CGI: Clinical Global Impression Scale; IA: Inattention; H-I:
Hyperactivity-Impulsivity; OD: Opposition-Defiance; CD: Conduct Disorder; P: Parent; C: Clinician.
*For CGI-Improvement Subscale assessments, 2
nd week was accepted as baseline.
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cent Behavior Disorders scale (inattention, hyperactivity-
impulsivity, opposition defiance and conduct problems).
Furthermore, we obtained significant differences
between baseline and Week 4 comparisons as well as
between baseline and Week 8 comparisons on the HI-
P&C, OD-P, CD-P&C and CGI-S&I subscales. The IA-C
and OD-C subscale comparisons revealed significant dif-
ferences between baseline and Week 4 plus Week 8 as
well as between Week 4 and 8. A statistically significant
difference was present between baseline and Week 8 on
the IA-P subscale. These results show that by Week 4,
both parents and the clinician reported significant
improvements on all four symptom areas and in global
disease severity (with the exception of the IA-P sub-
scale) after risperidone was administered. We interpret
this result to mean that the beneficial effects of risperi-
done appear within one month. This finding is impor-
tant when we consider that these children are at great
risk to self-injure and have severely disturbed relation-
ships. We do not think the benefits of this treatment are
related to the sedation that m a yo c c u ra sas i d ee f f e c t .
Sedation occurred only in two patients and disappeared
after two weeks. Previous studies have also stated in
that risperidone is an effective treatment for aggression
and that improvement is not related to sedation [7,24].
Our results were consistent with previous studies that
have assessed risperidone to treat disruptive behavior
problems. Some of these studies used short-term dou-
ble-blind methods; others used randomized controlled
trials with child and adolescent patients [7,19,24]. The
results of these studies suggest that risperidone is an
effective agent to control the aggression and destructive
behavior of children and adolescents with conduct dis-
order. In addition, long-term extension studies were
conducted in either a open-label fashion [29-31] or a
randomized, double-blind, placebo-controlled design
[32]; again, risperidone was safe and effective when used
as a maintenance treatment. Most of these studies were
conducted with children and adolescents with below
average IQs.
In a retrospective study of eight aggressive preschoo-
lers without pervasive development disorder and comor-
bid diagnoses of attention deficit hyperactivity, bipolar,
intermittent explosive and anxiety disorders, a risperi-
done treatment from 1 to 10 months in combination
with therapy was effective in controlling aggression [45].
This study reported an 88% response rate and a 36%
reduction in the CGI-Severity score. Significant weight
gains were an adverse event of the treatment. Our study
is similar to this previous study in terms of the age and
symptoms of the patients; however, the study design,
comorbid diagnosis and combination of other treat-
ments are important differences. Our study found a
more impressive response rate (100%) and a reduction
in the CGI-Severity score (78%). The large difference in
response may be related to the exclusion of children
with comorbid diagnoses from our study.
Pandina et al. reviewed pilot studies, large clinical
trials, and long-term open-label studies with more than
800 patients diagnosed with DBD [20]. Risperidone
doses of 0.02 to 0.06 mg/kg/day were associated with
target symptom improvement compared to placebo
within one to four weeks of treatment. The most com-
mon side effects reported in the reviewed studies were
somnolence, weight gain, headache, rhinitis, vomiting,
dyspepsia and an increase in prolactin. Prolactin levels
rapidly increased during the first month of treatment
and then declined over the following year. The inci-
dence of extrapyramidal side effects was low. Although
sedation was reported frequently in these studies, signifi-
cant drops in verbal learning or attention were not
found. Moreover, cognitive functioning improved on
several measures.
Unexpectedly, our study did not find any statistically
significant weight gains in patients after 2 months (par-
ticipant mean weight = 16 kg at baseline; mean weight
= 16.3 kg at Week 8). Furthermore, parents did not
report increased appetites in their children. This finding
is not consistent with previous studies showing that
weight gain occurred in several of the double-blind, pla-
cebo-controlled trials [20]. Note, however, that our
study was short term, and weight gain might have been
observed at a long-term follow up. Weight gain should
be carefully monitored to prevent metabolic syndrome
or Type-2 diabetes.
In addition to weight gain, some adverse effects such
as flu-like symptoms and mild gastrointestinal symp-
toms were frequently reported in previous studies. We
did not observe these side effects in our patients
(excluding the nausea and vomiting that occurred in the
child with acute dystonia). We did not use a specific
test to assess patient cognitive function; however, at the
clinical follow-up visit, parents were asked but did not
report any cognitive impairment. Only two children had
symptoms of sedation at the beginning of the treatment.
Some parents stated that after treatment, their child
maintained better focus on daily activities and play and
constructed better social relationships. We found a sig-
nificant decrease on the inattention subscale score of
the T-DSM-IV-S, meaning that patients’ attention
improved. This finding is consistent with another risper-
idone trial that was conducted using youths with CD
[58]. However, Findling et al. did not find that risperi-
done was associated with improvement in attention [24];
thus, this result should be interpreted cautiously.
The seven fold increase in prolactin was an expected
but important outcome of risperidone treatment.
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Elevated prolactin levels are one of the most commonly
reported outcomes of risperidone treatment in previous
studies. In some of the previous studies, these elevations
were related to clinical adverse events such as gyneco-
mastia, transient amenorrhea, or galactorrhea [29,31]
and in some others were not related [7,19]. Pandina et
al. stated in their review that hyperprolactinemia asso-
ciated with risperidone treatment may be a transitory
phenomenon of limited clinical significance; further-
more, they emphasized the need for additional studies
[20]. In a study conducted with 25 children with autism
between 3.9 and 7 years old, hyperprolactinemia due to
risperidone treatment was not significantly correlated
with age, weight, dosage amount or clinical outcomes
[59]. Dunbar et al. found that the prolactin net area
under curve (AUC) was not associated with a deviation
from expected growth [60]. Moreover, they did not find
a statistically significant correlation between prolactin
levels and sexual maturation during risperidone treat-
ment. The potential adverse effects of hyperprolactine-
mia, such as growth and maturation, must be carefully
observed and considered when treating patients who
experience prolacin elevation. Furthermore, future stu-
dies should investigate the effects of risperidone-related
prolactin increases in young populations.
Other than prolactin levels, there were no laboratory
test abnormalities (i.e., blood biochemistry, complete
blood count or ECG). A short-term risperidone treat-
ment conducted with 120 children and adolescents
between the ages of 3 and 17 reported a non-significant
alkaline phosphatase elevation in 52.5% of patients and
a marked liver enzyme elevation in 0.8% of patients [61].
The authors stated that concomitant medication use was
allowed in the study.
Study Limitations
Few studies have examined the psychopharmacologic
treatment of severely aggressive preschoolers with con-
duct disorder and otherwise normal developments. This
study helps construct a baseline for future studies; how-
ever, highlighting the important limitations of this study
is necessary. First of all, we planned to start this study
with 16 participants, but four patients withdrew at the
first meeting. Another four patients dropped out
because they could not attend follow up visits. This
small sample size (eight patients) clearly limits the sta-
tistical power of our analyses. Related to the statistical
analyses, we did not perform multiple comparisons or
control for other variables. Thus, we could not provide
a specific estimate of the statistical power used to com-
pute sample size, so the results should be considered as
hypothesis generating rather than confirmatory. Another
limitation is the shortage of assessment tools designed
for preschoolers. The T-DSM-IV scale is based on the
DSM-IV DBD diagnostic criteria, and although these
criteria are valid in preschoolers, age-appropriate adap-
tations are needed. The short duration of this study is
other important limitation. Although we did not detect
patient weight gain, the risks of lipid metabolism related
to antipsychotics are well documented. Furthermore, we
do not know much about the long-term effects of pro-
lactin increase in preschoolers. 8-week study duration is
a short time to determine the safety of this procedure;
long-term trials are necessary.
Conclusion
The validity of conduct disorder has been recently well-
established in preschoolers. Early intervention decreases
the progress of the disease. Psychotherapy modalities
such as parent training and behavioral therapies includ-
ing the parents are first-line treatment modalities. How-
ever, for those cases who fail to respond to first-line
treatments, clinicians face the challenge of the lack of
empirical data on the efficacy and side effects of medica-
tions for young children. Risperidone is the most studied
agent in youths to treat conduct disorder, but most of
t h e s ed a t ac o m ef r o ms c h o o l - age children. Studies with
preschoolers are usually conducted with developmentally
delayed children. We believe, however, that treating
severe behavioral problems in normally developing pre-
schoolers needs investigation because adverse drug
effects and drug efficacy may differ from older children.
This preliminary open-label 8-week study suggests that a
low dose of risperidone may be an effective treatment for
conduct problems in preschoolers with an otherwise nor-
mal development and average intelligence. This drug was
well tolerated with a small dosage titration and close
monitoring. The results of this study should be inter-
preted as preliminary hypothesis-generating data because
of its important limitations. Note once more that medica-
tions should only be considered in preschoolers if other
behavioral treatment modalities and family interventions
fail to provide benefits and the disorder obviously dis-
turbs the development of the child by affecting their
social relationships as well as their bodily and mental
health. If the medication is started, it should be used cau-
tiously with frequent follow-up interviews and close
monitoring. Additional short-term and long-term rando-
mized placebo-controlled trials are needed to evaluate
the safety and efficacy of risperidone treatment in
preschoolers.
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